SAN DIEGO,Feb. 26, 2024/PRNewswire/ --Neomorph, Inc.today announced it has entered into a collaboration and licensing agreement with global healthcare company Novo Nordisk to discover, develop and commercialize molecular glue degr...
and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. As part of...
Biogen on Tuesday became the latest company to partner on the increasingly popular subject, teaming up with private San Diego biotech Neomorph. Biogen will pay Neomorph an undisclosed upfront sum while promising up to $1.45 billion in various milestones and royalties in the mid-single-digit to ...
SAN DIEGO, 26 de febrero, 2024 /PRNewswire/ -- Neomorph, Inc. anunció hoy que ha firmado un acuerdo de colaboración y licencia con la empresa mundial de atención médica Novo Nordisk para descubrir, desarrollar y comercializar degradadores de peg...